Affimed N.V. announced that Dr. Adi Hoess, Chief Executive Officer and member of the Management Board, will step down effective January 15, 2024. Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011. The Company has initiated a comprehensive search process to identify a successor CEO. In the interim, Dr. Andreas Harstrick, Chief Medical Officer of the Company, will assume the role of interim CEO until a new CEO is appointed. Andreas has nearly 25 years of extensive experience in cancer drug development, including strategic leadership of three global phase 3 programs of new biological entities that culminated in global regulatory approvals, and multiple pivotal phase 3 studies. Given the clinical focus of the company, Andreas is well positioned to lead the company through the transition to a new CEO while continuing as CMO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AFMD:
- Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
- Affimed to sell AbCheck to Ampersand Biomedicines for $6M
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
- Affimed to hold a pharmaceutical update conference call
- Affimed discontinues enrollment in AFM24-102 into gastric cancer, basket cohorts
